MedTrace Logo

Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma

NCT02939183 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2024-09-26

Study results available
· View outcomes & findings →

Summary

A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in participants with relapsed refractory multiple myeloma.

Conditions

Interventions

DRUG

Immediate Release (IR) Formulation

Immediate Release (IR) Formulation

DRUG

Gastro-Retentive (GR) Formulation

Gastro-Retentive (GR) Formulation

DRUG

Dexamethasone

Dexamethasone

DRUG

Pomalidomide

Pomalidomide

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-17
Primary Completion
2022-10-06
Completion
2022-10-06

Countries

  • United States
  • Australia
  • Canada
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02939183 on ClinicalTrials.gov